Revenue - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended
	May 31, 2023	Feb. 28, 2019	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			$ 41,873,000		$ 37,647,000
Deferred revenue			91,030,000			$ 93,423,000
Immune Medicine Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			4,700,000		9,100,000
Medicare Reimbursements
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			1,500,000		$ 1,000,000
MRD Development Agreements | Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable			430,500,000
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement				$ 7,700,000
Non-refundable upfront payments received		$ 300,000,000.0	300,000,000.0
Expected revenue through milestone payments			$ 1,800,000,000
Additional transaction price of regulatory milestone	$ 10,000,000
Genentech Collaboration Agreement | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Additional transaction price of regulatory milestone	$ 10,000,000.0
Genentech Collaboration Agreement | Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period			9 years
Genentech Collaboration Agreement | Maximum | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			$ 65,000,000.0
Genentech Collaboration Agreement | Maximum | Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			300,000,000.0
Genentech Collaboration Agreement | Maximum | Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			$ 1,430,000,000